TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for he…
An institutional-grade, numbers-driven thesis on TELA — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates TELA Bio, Inc. (TELA) 62/100 with a 12-month base-case forecast of $8.25 — +1043.6% versus the current price of $0.72. TELA Bio, Inc. trades at $0.72 in the Healthcare sector, with a market capitalisation of $32.3M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for TELA is $8.25, implying +1043.6% versus the current price. The model's 12-month scenario range runs from $0.43 (bear) to $0.77 (bull), with a base case of $0.56.
On the fundamentals, TELA Bio shows a P/E of -0.9, trailing revenue of $80.3M, revenue growth of +15.8% YoY. This page also tracks TELA's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
TELA currently carries a TradersQuant composite score of 62/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $8.25 implies +1043.6% from $0.72. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for TELA is $8.25, about +1043.6% versus the latest price of $0.72. Consensus is based on 8 analysts.
TradersQuant's 12-month model forecast for TELA is a base case of $0.56, ranging from $0.43 (bear) to $0.77 (bull), an expected return of -22.9%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for TELA over the next 12 months is $0.56 in the base case (bear $0.43, bull $0.77), versus today's price of $0.72. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for TELA — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates TELA's fair value at $8.25, implying +1043.6% of expected upside versus the current price.
TELA Bio does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
